STOCKHOLM, Sweden, Oct. 12, 2005 (PRIMEZONE) -- Approval for the next generation of Elekta's Synergy(R) Platform and X-ray Volume Imaging by Canada's government health agency, Health Canada, gives Canadian clinicians effective new workflow tools for IGRT and 4D Adaptive(TM) radiation therapy.
Image Guided Radiation Therapy (IGRT) is the next generation in radiation oncology treatment accuracy, giving clinicians the ability to image a patient at the point of treatment, make corrections to better target a tumor, and avoid surrounding healthy tissue. Elekta was the first company to develop IGRT and the first to bring it to market, and remains the world leader in this next generation of treatment accuracy.
With more than 4,000 clinical images from 20 installations, and more than 50 systems scheduled to be installed, Elekta's system has proven its clinical effectiveness and is tantalizing clinicians with its future potential.
For further information, please contact:
International:
Peter Ejemyr Group VP Corporate Communications, Elekta AB Tel: +46 733 611 000 e-mail: peter.ejemyr@elekta.com
US:
Lars Jonsteg VP Investor Relations North America, Elekta, USA Tel: +46 708 78 37 35 e-mail: lars.jonsteg@elekta.com
About Elekta
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include among others Leksell Gamma Knife(R) for non-invasive treatment of brain surgery and Elekta Synergy(R) for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, The Elekta Group is the world's largest supplier of oncology software.
Elekta's systems and solutions are used at over 3,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.
With approx. 1700 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download: http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=139721&fn=wkr0001.pdf
PDF version